

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury[3]. Nateglinide is an oral hypoglycemic agent approved for use alone or in combination with metformin as an adjunct to diet and exercise for the treatment of type 2 diabetes mellitus. Nateglinide is highly bound to plasma proteins, is metabolized extensively by the liver, and has an elimination half-life of 1.4 hours. Several clinical trials of nateglinide, alone and in combination with other oral hypoglycemic agents, have found the drug to be safe, effective, and well tolerated. The most common adverse effects are nausea, diarrhea, dizziness, and lightheadedness. There is a potential for interactions between nateglinide and medications affected by the cytochrome P-450 isoenzyme system[4]. Nateglinide 120 mg plus metformin 500 mg, both 3 times daily, conferred greater glycaemic improvement than either drug given alone, and nateglinide 60 or 120 mg 3 times daily plus metformin 1 g twice daily was superior to metformin plus placebo[5]. |
| Concentration | Treated Time | Description | References | |
| BRIN-BD11 cells | 100 μM | 18 h | 18-hour exposure to 100 mM nateglinide abolished the acute insulinotropic effects of nateglinide, tolbutamide, and glibenclamide, but did not affect the insulinotropic effect of efaroxan. | Br J Pharmacol. 2004 May;142(2):367-73. |
| BRIN-BD11 cells | 10–400 μM | 20 min | Nateglinide induced a concentration-dependent increase in insulin release at non-stimulatory glucose concentrations and evoked K ATPchannel-independent insulin secretion in depolarized cells. | Br J Pharmacol. 2004 May;142(2):367-73. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Streptozotocin (STZ)-induced diabetic mice | Oral | 150 mg/kg | Every 3 days for 130 days | To evaluate the effectiveness of Ins@Alg/NG in regulating blood glucose levels in diabetic mice, results showed that Ins@Alg/NG significantly reduced blood glucose levels and restored pancreatic function. | Adv Sci (Weinh). 2023 Oct;10(29):e2301879 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03492580 | - | Completed | - | United States, New Jersey ... 展开 >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 收起 << | |
| NCT02456428 | - | Completed | - | Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 << | |
| NCT02475499 | - | Completed | - | Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 << | |
[4]Halas CJ. Nateglinide. Am J Health Syst Pharm. 2001;58(13):1200-1205
[5]Dunn CJ, Faulds D. Nateglinide. Drugs. 2000;60(3):607-617
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.15mL 0.63mL 0.32mL |
15.75mL 3.15mL 1.58mL |
31.50mL 6.30mL 3.15mL |
|
| CAS号 | 105816-04-4 |
| 分子式 | C19H27NO3 |
| 分子量 | 317.42 |
| SMILES Code | O=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O |
| MDL No. | MFCD00875706 |
| 别名 | 那格列奈 ;A4166; Senaglinide; Starlix; Fastic; DJN-608l; DJN 608; SDZ-DJN 608 |
| 运输 | 蓝冰 |
| InChI Key | OELFLUMRDSZNSF-OFLPRAFFSA-N |
| Pubchem ID | 5311309 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(330.79 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1